Korsana Biosciences, Inc. (KRSA) stock
Close on Nov 16, 2026Market cap $152.99MP/E –Yield –
Korsana Biosciences, Inc. saw revenue fall 12.6% to $1.90M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $152.99M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $152.99M
- P/E ratio
- –
- Price to sales
- 80.52
- Price to book
- 30.07
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.90M
- Net income
- -$6.71M
- EPS, diluted
- -$1.68
- Book value per share
- $1.20
- Diluted shares
- 4M
Trading
- Previous close
- $31.65
- Open
- $31.80
- Day's range
- $31.43 – $34.17
- Volume
- 319,840
- Average volume (20 days)
- 179,587
- 52-week range
- $7.19 – $59.36
- RSI (14 days)
- 55.3
- Volatility (1 year)
- 326.9%
- Relative volume
- 4.48×
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | KRSA | S&P 500 | Difference | KRSA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.9% | -3.1% | +4.0 pts | ||
| 3 months | +23.2% | -4.5% | +27.6 pts | ||
| Year to date | +267.6% | +9.4% | +258.3 pts | ||
| 1 year | +243.3% | +11.3% | +232.0 pts | ||
| 3 years | +135.8% | +70.4% | +65.4 pts | +33.1% | +19.4% |
| 5 years | -91.1% | +68.6% | −159.7 pts | -38.3% | +11.0% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Korsana Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously AnnouncedResults
- Results
- Results
- Update
- Update
About Korsana Biosciences
Pharmaceutical Preparations
Cyclerion is a biopharmaceutical company that develops treatments for serious neuropsychiatric disorders. Its lead development candidate, CYC-126, is an individualized therapy for adult patients with treatment-resistant depression. The treatment combines two intravenous anesthetics, propofol and dexmedetomidine, with a patient monitoring and delivery tool that assists anesthesiologists during administration in hospital procedure rooms or post-anesthesia care units. The company also holds legacy soluble guanylate cyclase stimulator assets, including out-licensed programs for rare kidney conditions.
Company profile, executives and historyKorsana Biosciences stock: common questions
What is Korsana Biosciences's stock price?
KRSA closed at $32.68 on Nov 16, 2026, up 3.25% on the day. Over the past 52 weeks it traded between $7.19 and $59.36.
What is Korsana Biosciences's market cap?
Korsana Biosciences was worth $152.99M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is KRSA's P/E ratio?
Korsana Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.68), so it has no meaningful P/E ratio.
How much revenue does Korsana Biosciences make?
Korsana Biosciences reported revenue of $1.90M for the twelve months to Jun 30, 2026, down 12.6% from a year earlier.
Does Korsana Biosciences pay a dividend?
No. Korsana Biosciences has not paid a cash dividend over the last twelve months.
How has KRSA stock performed over the past year?
Including dividends, KRSA returned +243.3% over the past year, against +11.3% for the S&P 500.
Who are Korsana Biosciences's competitors?
Companies most similar to Korsana Biosciences by business, industry and size include OVID, NRXP, DNTH, NEUP, XENE.
See a number that looks wrong?